Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

PRI-VENT FSGS: Preemptive Rituximab to Prevent Recurrent Focal Segmental Glomerulosclerosis Post-Transplant

NCT03763643 is registered in ClinicalTrials.gov with University of Minnesota as lead sponsor.

NCT NCT03763643
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03763643 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
PRI-VENT FSGS: Preemptive Rituximab to Prevent Recurrent Focal Segmental Glomerulosclerosis Post-Transplant
Lead sponsor
University of Minnesota
Phase
Phase 1
Overall status
Completed
Start date
July 1, 2019
Completion date
February 7, 2025
Enrollment
21 (actual)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

focal segmental glomerulosclerosis